Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Does the MarketBeat Community prefer CORT or RPRX?

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.26% of users gave Corcept Therapeutics an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Corcept Therapeutics	Outperform Votes 548 71.26%	Underperform Votes 221 28.74%
Royalty Pharma	Outperform Votes 327 67.98%	Underperform Votes 154 32.02%

Does the media refer more to CORT or RPRX?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 16 mentions for Corcept Therapeutics and 5 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.84 beat Corcept Therapeutics' score of 0.22 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CORT or RPRX?

Corcept Therapeutics presently has a consensus target price of $138.25, suggesting a potential upside of 91.30%. Royalty Pharma has a consensus target price of $47.33, suggesting a potential upside of 40.96%. Given Corcept Therapeutics' higher probable upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has more risk & volatility, CORT or RPRX?

Corcept Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Which has better valuation & earnings, CORT or RPRX?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$685.45M	11.18	$106.14M	$1.16	62.30
Royalty Pharma	$2.26B	8.34	$858.98M	$1.85	18.15

Do insiders and institutionals have more ownership in CORT or RPRX?

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 20.8% of Corcept Therapeutics shares are held by insiders. Comparatively, 18.9% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is CORT or RPRX more profitable?

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	22.35%	24.54%	20.24%
Royalty Pharma	37.94%	24.40%	14.01%

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.